- Home
- INMD vs TNGX Comparison
INMD vs TNGX Comparison
Compare INMD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMD
- TNGX
- Stock Information
- Founded
- INMD 2008
- TNGX 2014
- Country
- INMD Israel
- TNGX United States
- Employees
- INMD N/A
- TNGX N/A
- Industry
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- INMD Health Care
- TNGX Health Care
- Exchange
- INMD Nasdaq
- TNGX Nasdaq
- Market Cap
- INMD 896.9M
- TNGX 723.2M
- IPO Year
- INMD 2019
- TNGX N/A
- Fundamental
- Price
- INMD $14.83
- TNGX $6.53
- Analyst Decision
- INMD Hold
- TNGX Strong Buy
- Analyst Count
- INMD 6
- TNGX 6
- Target Price
- INMD $16.81
- TNGX $10.00
- AVG Volume (30 Days)
- INMD 953.5K
- TNGX 1.4M
- Earning Date
- INMD 10-29-2025
- TNGX 11-05-2025
- Dividend Yield
- INMD N/A
- TNGX N/A
- EPS Growth
- INMD 46.63
- TNGX N/A
- EPS
- INMD 2.54
- TNGX N/A
- Revenue
- INMD $401,561,000.00
- TNGX $24,296,000.00
- Revenue This Year
- INMD N/A
- TNGX $6.56
- Revenue Next Year
- INMD $5.30
- TNGX N/A
- P/E Ratio
- INMD $5.88
- TNGX N/A
- Revenue Growth
- INMD N/A
- TNGX N/A
- 52 Week Low
- INMD $13.14
- TNGX $1.03
- 52 Week High
- INMD $19.85
- TNGX $10.85
- Technical
- Relative Strength Index (RSI)
- INMD 51.94
- TNGX 47.47
- Support Level
- INMD $14.86
- TNGX $6.25
- Resistance Level
- INMD $15.48
- TNGX $7.40
- Average True Range (ATR)
- INMD 0.41
- TNGX 0.40
- MACD
- INMD 0.03
- TNGX -0.06
- Stochastic Oscillator
- INMD 45.68
- TNGX 24.35
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.